http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 28 Aug 2026 16:01:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/NurExone+Biologic+Inc.+to+Present+at+the+Moody+Capital+Solutions+2026+Disruptive+Growth+%26amp%3B+Life+Sciences+Conference/26997718.html <p align="justify">TORONTO and HAIFA, Israel, Aug. 28, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“<strong>NurExone</strong>” or the “<strong>Company</strong>”), a biotechnology company developing exosome-based regenerative therapies, today announced that it is scheduled to participate in the Moody Capital Solutions 2026 Disruptive Growth &amp; Life Sciences Conference, taking place September 9–10, 2026, in New York City.</p> <p align="justify">Yoram Drucker, Co-Founder, Chairman and Vice President of Strategic Development of NurExone, will deliver an investor presentation and participate in scheduled one-on-one meetings with investors. “As NurExone continues its preclinical development activities and preparations for potential http://www.streetinsider.com/Press+Releases/NurExone+Biologic+Inc.+to+Present+at+the+Moody+Capital+Solutions+2026+Disruptive+Growth+%26amp%3B+Life+Sciences+Conference/26997718.html Fri, 28 Aug 2026 16:01:00 -0400 J90 NRX NRXBF O.13737008 http://www.streetinsider.com/Press+Releases/NurExone+Biologic+Inc.+to+Present+at+the+Moody+Capital+Solutions+2026+Disruptive+Growth+%26amp%3B+Life+Sciences+Conference/26997718.html <p align="justify">TORONTO and HAIFA, Israel, Aug. 28, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“<strong>NurExone</strong>” or the “<strong>Company</strong>”), a biotechnology company developing exosome-based regenerative therapies, today announced that it is scheduled to participate in the Moody Capital Solutions 2026 Disruptive Growth &amp; Life Sciences Conference, taking place September 9–10, 2026, in New York City.</p> <p align="justify">Yoram Drucker, Co-Founder, Chairman and Vice President of Strategic Development of NurExone, will deliver an investor presentation and participate in scheduled one-on-one meetings with investors. “As NurExone continues its preclinical development activities and preparations for potential http://www.streetinsider.com/Press+Releases/NurExone+Biologic+Inc.+to+Present+at+the+Moody+Capital+Solutions+2026+Disruptive+Growth+%26amp%3B+Life+Sciences+Conference/26997718.html Fri, 28 Aug 2026 16:01:00 -0400 J90 NRX NRXBF O.13737008 http://www.streetinsider.com/Press+Releases/NurExone+Biologic+Inc.+to+Present+at+the+Moody+Capital+Solutions+2026+Disruptive+Growth+%26amp%3B+Life+Sciences+Conference/26997718.html <p align="justify">TORONTO and HAIFA, Israel, Aug. 28, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“<strong>NurExone</strong>” or the “<strong>Company</strong>”), a biotechnology company developing exosome-based regenerative therapies, today announced that it is scheduled to participate in the Moody Capital Solutions 2026 Disruptive Growth &amp; Life Sciences Conference, taking place September 9–10, 2026, in New York City.</p> <p align="justify">Yoram Drucker, Co-Founder, Chairman and Vice President of Strategic Development of NurExone, will deliver an investor presentation and participate in scheduled one-on-one meetings with investors. “As NurExone continues its preclinical development activities and preparations for potential http://www.streetinsider.com/Press+Releases/NurExone+Biologic+Inc.+to+Present+at+the+Moody+Capital+Solutions+2026+Disruptive+Growth+%26amp%3B+Life+Sciences+Conference/26997718.html Fri, 28 Aug 2026 16:01:00 -0400 J90 NRX NRXBF O.13737008 http://www.streetinsider.com/Press+Releases/NurExone+Biologic+Inc.+to+Present+at+the+Moody+Capital+Solutions+2026+Disruptive+Growth+%26amp%3B+Life+Sciences+Conference/26997718.html <p align="justify">TORONTO and HAIFA, Israel, Aug. 28, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“<strong>NurExone</strong>” or the “<strong>Company</strong>”), a biotechnology company developing exosome-based regenerative therapies, today announced that it is scheduled to participate in the Moody Capital Solutions 2026 Disruptive Growth &amp; Life Sciences Conference, taking place September 9–10, 2026, in New York City.</p> <p align="justify">Yoram Drucker, Co-Founder, Chairman and Vice President of Strategic Development of NurExone, will deliver an investor presentation and participate in scheduled one-on-one meetings with investors. “As NurExone continues its preclinical development activities and preparations for potential http://www.streetinsider.com/Press+Releases/NurExone+Biologic+Inc.+to+Present+at+the+Moody+Capital+Solutions+2026+Disruptive+Growth+%26amp%3B+Life+Sciences+Conference/26997718.html Fri, 28 Aug 2026 16:01:00 -0400 J90 NRX NRXBF O.13737008 http://www.streetinsider.com/Globe+Newswire/NurExone+Biologic+Inc.+to+Present+at+the+Moody+Capital+Solutions+2026+Disruptive+Growth+%26amp%3B+Life+Sciences+Conference/26997718.html <p align="justify">TORONTO and HAIFA, Israel, Aug. 28, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“<strong>NurExone</strong>” or the “<strong>Company</strong>”), a biotechnology company developing exosome-based regenerative therapies, today announced that it is scheduled to participate in the Moody Capital Solutions 2026 Disruptive Growth &amp; Life Sciences Conference, taking place September 9–10, 2026, in New York City.</p> <p align="justify">Yoram Drucker, Co-Founder, Chairman and Vice President of Strategic Development of NurExone, will deliver an investor presentation and participate in scheduled one-on-one meetings with investors. “As NurExone continues its preclinical development activities and preparations for potential http://www.streetinsider.com/Globe+Newswire/NurExone+Biologic+Inc.+to+Present+at+the+Moody+Capital+Solutions+2026+Disruptive+Growth+%26amp%3B+Life+Sciences+Conference/26997718.html Fri, 28 Aug 2026 16:01:00 -0400 J90 NRX NRXBF O.13737008 http://www.streetinsider.com/Globe+Newswire/NurExone+Biologic+Inc.+to+Present+at+the+Moody+Capital+Solutions+2026+Disruptive+Growth+%26amp%3B+Life+Sciences+Conference/26997718.html <p align="justify">TORONTO and HAIFA, Israel, Aug. 28, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“<strong>NurExone</strong>” or the “<strong>Company</strong>”), a biotechnology company developing exosome-based regenerative therapies, today announced that it is scheduled to participate in the Moody Capital Solutions 2026 Disruptive Growth &amp; Life Sciences Conference, taking place September 9–10, 2026, in New York City.</p> <p align="justify">Yoram Drucker, Co-Founder, Chairman and Vice President of Strategic Development of NurExone, will deliver an investor presentation and participate in scheduled one-on-one meetings with investors. “As NurExone continues its preclinical development activities and preparations for potential http://www.streetinsider.com/Globe+Newswire/NurExone+Biologic+Inc.+to+Present+at+the+Moody+Capital+Solutions+2026+Disruptive+Growth+%26amp%3B+Life+Sciences+Conference/26997718.html Fri, 28 Aug 2026 16:01:00 -0400 J90 NRX NRXBF O.13737008 http://www.streetinsider.com/Globe+Newswire/NurExone+Biologic+Inc.+to+Present+at+the+Moody+Capital+Solutions+2026+Disruptive+Growth+%26amp%3B+Life+Sciences+Conference/26997718.html <p align="justify">TORONTO and HAIFA, Israel, Aug. 28, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“<strong>NurExone</strong>” or the “<strong>Company</strong>”), a biotechnology company developing exosome-based regenerative therapies, today announced that it is scheduled to participate in the Moody Capital Solutions 2026 Disruptive Growth &amp; Life Sciences Conference, taking place September 9–10, 2026, in New York City.</p> <p align="justify">Yoram Drucker, Co-Founder, Chairman and Vice President of Strategic Development of NurExone, will deliver an investor presentation and participate in scheduled one-on-one meetings with investors. “As NurExone continues its preclinical development activities and preparations for potential http://www.streetinsider.com/Globe+Newswire/NurExone+Biologic+Inc.+to+Present+at+the+Moody+Capital+Solutions+2026+Disruptive+Growth+%26amp%3B+Life+Sciences+Conference/26997718.html Fri, 28 Aug 2026 16:01:00 -0400 J90 NRX NRXBF O.13737008 http://www.streetinsider.com/Globe+Newswire/NurExone+Biologic+Inc.+to+Present+at+the+Moody+Capital+Solutions+2026+Disruptive+Growth+%26amp%3B+Life+Sciences+Conference/26997718.html <p align="justify">TORONTO and HAIFA, Israel, Aug. 28, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“<strong>NurExone</strong>” or the “<strong>Company</strong>”), a biotechnology company developing exosome-based regenerative therapies, today announced that it is scheduled to participate in the Moody Capital Solutions 2026 Disruptive Growth &amp; Life Sciences Conference, taking place September 9–10, 2026, in New York City.</p> <p align="justify">Yoram Drucker, Co-Founder, Chairman and Vice President of Strategic Development of NurExone, will deliver an investor presentation and participate in scheduled one-on-one meetings with investors. “As NurExone continues its preclinical development activities and preparations for potential http://www.streetinsider.com/Globe+Newswire/NurExone+Biologic+Inc.+to+Present+at+the+Moody+Capital+Solutions+2026+Disruptive+Growth+%26amp%3B+Life+Sciences+Conference/26997718.html Fri, 28 Aug 2026 16:01:00 -0400 J90 NRX NRXBF O.13737008 http://www.streetinsider.com/Board+Changes/NurExone+names+David+Stolick+to+board%2C+hires+investor+firm/26828408.html <p>NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) has appointed David Stolick to its board of directors, effective July 28, 2026, according to a company statement. Stolick succeeds the late James "Jay" Richardson.</p> <p>Stolick previously served as VP of Finance at V-Wave Ltd., a U.S.-Israeli medical device company acquired by Johnson & Johnson in October 2024. He has also held the roles of CFO at Exalenz Bioscience and BrainStorm Cell Therapeutics, and Corporate Controller at M-Systems. He holds a B.A. in Economics and Accounting from Ben-Gurion University and is a Certified Public Accountant.</p> <p>"I am honored to join NurExone's Board," Stolick http://www.streetinsider.com/Board+Changes/NurExone+names+David+Stolick+to+board%2C+hires+investor+firm/26828408.html Tue, 28 Jul 2026 17:24:32 -0400 A.34261125 A.36078215 A.60005111 J90 NRX NRXBF O.02555813 O.06580126 O.13737008 O.13804794 http://www.streetinsider.com/Board+Changes/NurExone+names+David+Stolick+to+board%2C+hires+investor+firm/26828408.html <p>NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) has appointed David Stolick to its board of directors, effective July 28, 2026, according to a company statement. Stolick succeeds the late James "Jay" Richardson.</p> <p>Stolick previously served as VP of Finance at V-Wave Ltd., a U.S.-Israeli medical device company acquired by Johnson & Johnson in October 2024. He has also held the roles of CFO at Exalenz Bioscience and BrainStorm Cell Therapeutics, and Corporate Controller at M-Systems. He holds a B.A. in Economics and Accounting from Ben-Gurion University and is a Certified Public Accountant.</p> <p>"I am honored to join NurExone's Board," Stolick http://www.streetinsider.com/Board+Changes/NurExone+names+David+Stolick+to+board%2C+hires+investor+firm/26828408.html Tue, 28 Jul 2026 17:24:32 -0400 A.34261125 A.36078215 A.60005111 J90 NRX NRXBF O.02555813 O.06580126 O.13737008 O.13804794 http://www.streetinsider.com/Board+Changes/NurExone+names+David+Stolick+to+board%2C+hires+investor+firm/26828408.html <p>NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) has appointed David Stolick to its board of directors, effective July 28, 2026, according to a company statement. Stolick succeeds the late James "Jay" Richardson.</p> <p>Stolick previously served as VP of Finance at V-Wave Ltd., a U.S.-Israeli medical device company acquired by Johnson & Johnson in October 2024. He has also held the roles of CFO at Exalenz Bioscience and BrainStorm Cell Therapeutics, and Corporate Controller at M-Systems. He holds a B.A. in Economics and Accounting from Ben-Gurion University and is a Certified Public Accountant.</p> <p>"I am honored to join NurExone's Board," Stolick http://www.streetinsider.com/Board+Changes/NurExone+names+David+Stolick+to+board%2C+hires+investor+firm/26828408.html Tue, 28 Jul 2026 17:24:32 -0400 A.34261125 A.36078215 A.60005111 J90 NRX NRXBF O.02555813 O.06580126 O.13737008 O.13804794 http://www.streetinsider.com/Board+Changes/NurExone+names+David+Stolick+to+board%2C+hires+investor+firm/26828408.html <p>NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) has appointed David Stolick to its board of directors, effective July 28, 2026, according to a company statement. Stolick succeeds the late James "Jay" Richardson.</p> <p>Stolick previously served as VP of Finance at V-Wave Ltd., a U.S.-Israeli medical device company acquired by Johnson & Johnson in October 2024. He has also held the roles of CFO at Exalenz Bioscience and BrainStorm Cell Therapeutics, and Corporate Controller at M-Systems. He holds a B.A. in Economics and Accounting from Ben-Gurion University and is a Certified Public Accountant.</p> <p>"I am honored to join NurExone's Board," Stolick http://www.streetinsider.com/Board+Changes/NurExone+names+David+Stolick+to+board%2C+hires+investor+firm/26828408.html Tue, 28 Jul 2026 17:24:32 -0400 A.34261125 A.36078215 A.60005111 J90 NRX NRXBF O.02555813 O.06580126 O.13737008 O.13804794 http://www.streetinsider.com/Board+Changes/NurExone+names+David+Stolick+to+board%2C+hires+investor+firm/26828408.html <p>NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) has appointed David Stolick to its board of directors, effective July 28, 2026, according to a company statement. Stolick succeeds the late James "Jay" Richardson.</p> <p>Stolick previously served as VP of Finance at V-Wave Ltd., a U.S.-Israeli medical device company acquired by Johnson & Johnson in October 2024. He has also held the roles of CFO at Exalenz Bioscience and BrainStorm Cell Therapeutics, and Corporate Controller at M-Systems. He holds a B.A. in Economics and Accounting from Ben-Gurion University and is a Certified Public Accountant.</p> <p>"I am honored to join NurExone's Board," Stolick http://www.streetinsider.com/Board+Changes/NurExone+names+David+Stolick+to+board%2C+hires+investor+firm/26828408.html Tue, 28 Jul 2026 17:24:32 -0400 A.34261125 A.36078215 A.60005111 J90 NRX NRXBF O.02555813 O.06580126 O.13737008 O.13804794 http://www.streetinsider.com/Board+Changes/NurExone+names+David+Stolick+to+board%2C+hires+investor+firm/26828408.html <p>NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) has appointed David Stolick to its board of directors, effective July 28, 2026, according to a company statement. Stolick succeeds the late James "Jay" Richardson.</p> <p>Stolick previously served as VP of Finance at V-Wave Ltd., a U.S.-Israeli medical device company acquired by Johnson & Johnson in October 2024. He has also held the roles of CFO at Exalenz Bioscience and BrainStorm Cell Therapeutics, and Corporate Controller at M-Systems. He holds a B.A. in Economics and Accounting from Ben-Gurion University and is a Certified Public Accountant.</p> <p>"I am honored to join NurExone's Board," Stolick http://www.streetinsider.com/Board+Changes/NurExone+names+David+Stolick+to+board%2C+hires+investor+firm/26828408.html Tue, 28 Jul 2026 17:24:32 -0400 A.34261125 A.36078215 A.60005111 J90 NRX NRXBF O.02555813 O.06580126 O.13737008 O.13804794 http://www.streetinsider.com/Board+Changes/NurExone+names+David+Stolick+to+board%2C+hires+investor+firm/26828408.html <p>NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) has appointed David Stolick to its board of directors, effective July 28, 2026, according to a company statement. Stolick succeeds the late James "Jay" Richardson.</p> <p>Stolick previously served as VP of Finance at V-Wave Ltd., a U.S.-Israeli medical device company acquired by Johnson & Johnson in October 2024. He has also held the roles of CFO at Exalenz Bioscience and BrainStorm Cell Therapeutics, and Corporate Controller at M-Systems. He holds a B.A. in Economics and Accounting from Ben-Gurion University and is a Certified Public Accountant.</p> <p>"I am honored to join NurExone's Board," Stolick http://www.streetinsider.com/Board+Changes/NurExone+names+David+Stolick+to+board%2C+hires+investor+firm/26828408.html Tue, 28 Jul 2026 17:24:32 -0400 A.34261125 A.36078215 A.60005111 J90 NRX NRXBF O.02555813 O.06580126 O.13737008 O.13804794 http://www.streetinsider.com/Board+Changes/NurExone+names+David+Stolick+to+board%2C+hires+investor+firm/26828408.html <p>NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) has appointed David Stolick to its board of directors, effective July 28, 2026, according to a company statement. Stolick succeeds the late James "Jay" Richardson.</p> <p>Stolick previously served as VP of Finance at V-Wave Ltd., a U.S.-Israeli medical device company acquired by Johnson & Johnson in October 2024. He has also held the roles of CFO at Exalenz Bioscience and BrainStorm Cell Therapeutics, and Corporate Controller at M-Systems. He holds a B.A. in Economics and Accounting from Ben-Gurion University and is a Certified Public Accountant.</p> <p>"I am honored to join NurExone's Board," Stolick http://www.streetinsider.com/Board+Changes/NurExone+names+David+Stolick+to+board%2C+hires+investor+firm/26828408.html Tue, 28 Jul 2026 17:24:32 -0400 A.34261125 A.36078215 A.60005111 J90 NRX NRXBF O.02555813 O.06580126 O.13737008 O.13804794 http://www.streetinsider.com/Board+Changes/NurExone+names+David+Stolick+to+board%2C+hires+investor+firm/26828408.html <p>NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) has appointed David Stolick to its board of directors, effective July 28, 2026, according to a company statement. Stolick succeeds the late James "Jay" Richardson.</p> <p>Stolick previously served as VP of Finance at V-Wave Ltd., a U.S.-Israeli medical device company acquired by Johnson & Johnson in October 2024. He has also held the roles of CFO at Exalenz Bioscience and BrainStorm Cell Therapeutics, and Corporate Controller at M-Systems. He holds a B.A. in Economics and Accounting from Ben-Gurion University and is a Certified Public Accountant.</p> <p>"I am honored to join NurExone's Board," Stolick http://www.streetinsider.com/Board+Changes/NurExone+names+David+Stolick+to+board%2C+hires+investor+firm/26828408.html Tue, 28 Jul 2026 17:24:32 -0400 A.34261125 A.36078215 A.60005111 J90 NRX NRXBF O.02555813 O.06580126 O.13737008 O.13804794 http://www.streetinsider.com/Board+Changes/NurExone+names+David+Stolick+to+board%2C+hires+investor+firm/26828408.html <p>NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) has appointed David Stolick to its board of directors, effective July 28, 2026, according to a company statement. Stolick succeeds the late James "Jay" Richardson.</p> <p>Stolick previously served as VP of Finance at V-Wave Ltd., a U.S.-Israeli medical device company acquired by Johnson & Johnson in October 2024. He has also held the roles of CFO at Exalenz Bioscience and BrainStorm Cell Therapeutics, and Corporate Controller at M-Systems. He holds a B.A. in Economics and Accounting from Ben-Gurion University and is a Certified Public Accountant.</p> <p>"I am honored to join NurExone's Board," Stolick http://www.streetinsider.com/Board+Changes/NurExone+names+David+Stolick+to+board%2C+hires+investor+firm/26828408.html Tue, 28 Jul 2026 17:24:32 -0400 A.34261125 A.36078215 A.60005111 J90 NRX NRXBF O.02555813 O.06580126 O.13737008 O.13804794 http://www.streetinsider.com/Press+Releases/Corporate+Updates+%E2%80%93+NurExone+appoints+Mr.+David+Stolick+to+the+Board+of+Directors/26828407.html <p align="justify">TORONTO, Ontario and HAIFA, Israel, July 29, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-based regenerative therapies, announces the appointment of Mr. David Stolick to its Board of Directors, effective July 28, 2026. Mr. Stolick succeeds the late James &quot;Jay&quot; Richardson, whose leadership helped shape NurExone during its formative years.</p> <p align="justify">“Jay was much more than a director. He was a dealmaker, a trusted business advisor, our presence on the ground in Canada, and a true friend of the Company. He believed http://www.streetinsider.com/Press+Releases/Corporate+Updates+%E2%80%93+NurExone+appoints+Mr.+David+Stolick+to+the+Board+of+Directors/26828407.html Tue, 28 Jul 2026 17:24:00 -0400 A.34261125 A.36078215 A.60005111 J90 NRX NRXBF O.02555813 O.06580126 O.13737008 O.13804794 http://www.streetinsider.com/Press+Releases/Corporate+Updates+%E2%80%93+NurExone+appoints+Mr.+David+Stolick+to+the+Board+of+Directors/26828407.html <p align="justify">TORONTO, Ontario and HAIFA, Israel, July 29, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-based regenerative therapies, announces the appointment of Mr. David Stolick to its Board of Directors, effective July 28, 2026. Mr. Stolick succeeds the late James &quot;Jay&quot; Richardson, whose leadership helped shape NurExone during its formative years.</p> <p align="justify">“Jay was much more than a director. He was a dealmaker, a trusted business advisor, our presence on the ground in Canada, and a true friend of the Company. He believed http://www.streetinsider.com/Press+Releases/Corporate+Updates+%E2%80%93+NurExone+appoints+Mr.+David+Stolick+to+the+Board+of+Directors/26828407.html Tue, 28 Jul 2026 17:24:00 -0400 A.34261125 A.36078215 A.60005111 J90 NRX NRXBF O.02555813 O.06580126 O.13737008 O.13804794 http://www.streetinsider.com/Press+Releases/Corporate+Updates+%E2%80%93+NurExone+appoints+Mr.+David+Stolick+to+the+Board+of+Directors/26828407.html <p align="justify">TORONTO, Ontario and HAIFA, Israel, July 29, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-based regenerative therapies, announces the appointment of Mr. David Stolick to its Board of Directors, effective July 28, 2026. Mr. Stolick succeeds the late James &quot;Jay&quot; Richardson, whose leadership helped shape NurExone during its formative years.</p> <p align="justify">“Jay was much more than a director. He was a dealmaker, a trusted business advisor, our presence on the ground in Canada, and a true friend of the Company. He believed http://www.streetinsider.com/Press+Releases/Corporate+Updates+%E2%80%93+NurExone+appoints+Mr.+David+Stolick+to+the+Board+of+Directors/26828407.html Tue, 28 Jul 2026 17:24:00 -0400 A.34261125 A.36078215 A.60005111 J90 NRX NRXBF O.02555813 O.06580126 O.13737008 O.13804794 http://www.streetinsider.com/Press+Releases/Corporate+Updates+%E2%80%93+NurExone+appoints+Mr.+David+Stolick+to+the+Board+of+Directors/26828407.html <p align="justify">TORONTO, Ontario and HAIFA, Israel, July 29, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-based regenerative therapies, announces the appointment of Mr. David Stolick to its Board of Directors, effective July 28, 2026. Mr. Stolick succeeds the late James &quot;Jay&quot; Richardson, whose leadership helped shape NurExone during its formative years.</p> <p align="justify">“Jay was much more than a director. He was a dealmaker, a trusted business advisor, our presence on the ground in Canada, and a true friend of the Company. He believed http://www.streetinsider.com/Press+Releases/Corporate+Updates+%E2%80%93+NurExone+appoints+Mr.+David+Stolick+to+the+Board+of+Directors/26828407.html Tue, 28 Jul 2026 17:24:00 -0400 A.34261125 A.36078215 A.60005111 J90 NRX NRXBF O.02555813 O.06580126 O.13737008 O.13804794 http://www.streetinsider.com/Press+Releases/Corporate+Updates+%E2%80%93+NurExone+appoints+Mr.+David+Stolick+to+the+Board+of+Directors/26828407.html <p align="justify">TORONTO, Ontario and HAIFA, Israel, July 29, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-based regenerative therapies, announces the appointment of Mr. David Stolick to its Board of Directors, effective July 28, 2026. Mr. Stolick succeeds the late James &quot;Jay&quot; Richardson, whose leadership helped shape NurExone during its formative years.</p> <p align="justify">“Jay was much more than a director. He was a dealmaker, a trusted business advisor, our presence on the ground in Canada, and a true friend of the Company. He believed http://www.streetinsider.com/Press+Releases/Corporate+Updates+%E2%80%93+NurExone+appoints+Mr.+David+Stolick+to+the+Board+of+Directors/26828407.html Tue, 28 Jul 2026 17:24:00 -0400 A.34261125 A.36078215 A.60005111 J90 NRX NRXBF O.02555813 O.06580126 O.13737008 O.13804794 http://www.streetinsider.com/Press+Releases/Corporate+Updates+%E2%80%93+NurExone+appoints+Mr.+David+Stolick+to+the+Board+of+Directors/26828407.html <p align="justify">TORONTO, Ontario and HAIFA, Israel, July 29, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-based regenerative therapies, announces the appointment of Mr. David Stolick to its Board of Directors, effective July 28, 2026. Mr. Stolick succeeds the late James &quot;Jay&quot; Richardson, whose leadership helped shape NurExone during its formative years.</p> <p align="justify">“Jay was much more than a director. He was a dealmaker, a trusted business advisor, our presence on the ground in Canada, and a true friend of the Company. He believed http://www.streetinsider.com/Press+Releases/Corporate+Updates+%E2%80%93+NurExone+appoints+Mr.+David+Stolick+to+the+Board+of+Directors/26828407.html Tue, 28 Jul 2026 17:24:00 -0400 A.34261125 A.36078215 A.60005111 J90 NRX NRXBF O.02555813 O.06580126 O.13737008 O.13804794 http://www.streetinsider.com/Press+Releases/Corporate+Updates+%E2%80%93+NurExone+appoints+Mr.+David+Stolick+to+the+Board+of+Directors/26828407.html <p align="justify">TORONTO, Ontario and HAIFA, Israel, July 29, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-based regenerative therapies, announces the appointment of Mr. David Stolick to its Board of Directors, effective July 28, 2026. Mr. Stolick succeeds the late James &quot;Jay&quot; Richardson, whose leadership helped shape NurExone during its formative years.</p> <p align="justify">“Jay was much more than a director. He was a dealmaker, a trusted business advisor, our presence on the ground in Canada, and a true friend of the Company. He believed http://www.streetinsider.com/Press+Releases/Corporate+Updates+%E2%80%93+NurExone+appoints+Mr.+David+Stolick+to+the+Board+of+Directors/26828407.html Tue, 28 Jul 2026 17:24:00 -0400 A.34261125 A.36078215 A.60005111 J90 NRX NRXBF O.02555813 O.06580126 O.13737008 O.13804794